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Abstract
Staphylococcus aureus has emerged as a significant pathogen causing severe invasive disease in otherwise healthy people.
Despite considerable advances in understanding the epidemiology, resistance mechanisms, and virulence factors produced
by the bacteria, there is limited knowledge of the in vivo host immune response to acute, invasive S. aureus infections.
Herein, we report that peripheral blood mononuclear cells from patients with severe S. aureus infections demonstrate a
distinctive and robust gene expression profile which is validated in a distinct group of patients and on a different microarray
platform. Application of a systems-wide modular analysis framework reveals significant over-expression of innate immunity
genes and under-expression of genes related to adaptive immunity. Simultaneous flow cytometry analyses demonstrated
marked alterations in immune cell numbers, with decreased central memory CD4 and CD8 T cells and increased numbers of
monocytes. CD14+ monocyte numbers significantly correlated with the gene expression levels of genes related to the
innate immune response. These results demonstrate the value of applying a systems biology approach that reveals the
significant alterations in the components of circulating blood lymphocytes and monocytes in invasive S. aureus infections.
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Introduction
Staphylococcus aureus has emerged as a leading cause of both
community-associated and nosocomial invasive bacterial infections
in the United States, causing a wide spectrum of clinical illnesses
ranging from superficial soft tissue infections to severe, invasive
disease leading to considerable morbidity and mortality in
otherwise healthy children and adults [1–5]. As such, the US
Centers for Disease Control and Prevention has identified S. aureus
as a major public health problem in a recent population-based
surveillance study [6]. The increasing magnitude of S. aureus
disease burden, changes in bacterial susceptibility, and continued
poor patient outcomes with available antimicrobial therapies
clearly demonstrate a need to improve our understanding of its
pathogenesis in order to develop more effective therapeutic
strategies. To date, most efforts have been focused on advancing
our knowledge of the pathogen and its remarkable repertoire of
virulence factors [7]. To complement this progress, it is critical
that we also gain new insight into the host immune response to S.
aureus infection in a clinically relevant context.
Genome-wide analyses of blood leukocytes provide a global and
comprehensive assessment of the complexity of the immune
network and response to disease [8]. Previous work has
demonstrated the applicability of blood leukocyte microarray data
into clinical relevance, allowing for biomarker discovery leading to
improved diagnostic and prognostic indicators and innovative
therapeutics in autoimmune diseases [9–11] and cancer [12–15].
With advances in gene expression profiling and application of
microarray technology to the field of infectious diseases, we can
now more clearly define the host’s immune response to a pathogen
and identify a unique biosignature that is not limited by traditional
diagnostic or microbiologic techniques [16–18]. Peripheral blood
mononuclear cells (PBMCs) provide an accessible source of
molecular phenotypic information as they traffic within the
systemic circulation, to and from sites of infection and inflamma-
tion. When a pathogen infects the host, specific pattern-
recognition receptors expressed on leukocytes recognize unique
pathogen-associated molecular patterns displayed on microbes and
initiate the host’s innate and pro-inflammatory response to the
infection while simultaneously activating the adaptive immune
response [19,20]. The microbe-induced changes in host cells
demonstrate significant and stereotypical changes at the gene
expression level that are unique to the pathogen and can be
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used to advance our understanding of the human host response to
febrile illnesses such as malaria [17], acute dengue hemorrhagic
fever [17], HIV [23], and Kawasaki syndrome [17]. Our previous
work has demonstrated that PBMCs of children with different
acute infections carry distinct gene expression patterns that allow
discrimination between viral and bacterial pathogens and even
among subtypes of bacteria [24]. Despite different bacterial strains
and diverse clinical manifestations, we hypothesized that gene
expression analysis of PBMCs from children with acute invasive S.
aureus infections would demonstrate a characteristic and unique
host immune response and provide a novel and broad insight into
the pathogenesis of these infections. The present study was
designed to obtain a comprehensive characterization of the host
immune response to invasive S. aureus infections in children using a
combination of gene expression and flow cytometry analyses.
Results
Patient characteristics
Over a period of 4 years, samples from 53 previously healthy
patients hospitalized with invasive S. aureus infections and 24
healthy control subjects were analyzed. Patients were chosen
representing the clinical spectrum of acute severe S. aureus disease
including bacteremia, osteomyelitis, suppurative arthritis, pyo-
myositis, and pneumonia with empyema. Patients with a diagnosis
of staphylococcal toxic shock syndrome or polymicrobial infections
were excluded. Patient demographic data, clinical characteristics,
analysis group, and microarray platform are summarized in
Table 1. There were no statistical differences between the S.
aureus-infected children and their respective healthy controls with
regards to age, sex, or race in the training and test sets (Table 2).
Patients were enrolled only after a bacteriologic diagnosis was
established; the median time from patient hospitalization to
procurement of study blood sample was 4 days [IQ range 3–8
days]. Viral direct fluorescent antibody testing or culture of the
nasopharynx was obtained on 68 subjects (88%, 46 patients, 22
controls) and did not reveal the presence of a concomitant viral
infection.
Patients with culture-proven invasive S. aureus infections were
divided into 3 groups for analysis: training, test, and validation
sets. The training set of subjects composed of 20 children with
invasive S. aureus infections (median age 7.5 years; 11 methicillin-
resistant S. aureus, MRSA, and 9 methicillin-susceptible S. aureus,
MSSA) and 10 healthy controls (median age 6 years) matched for
age, sex, and race, were initially analyzed to identify the gene
expression profile in PBMCs from S. aureus-infected patients. As
expected, there were statistical differences in laboratory parame-
ters with higher total peripheral white blood cell count and percent
neutrophil count, but lower percent lymphocyte count and
hematocrit values in patients with S. aureus infections compared
with healthy controls (Table 2). The test set of subjects included
an independent group of 22 patients with S. aureus infection
(median age 7 years; 8 MSSA, 14 MRSA) and 10 healthy controls
(median age 6 years) and was used to validate the gene expression
profile in PBMCs from S. aureus-infected patients. As in the
training set, there were differences in laboratory values between
patients with S. aureus infection and healthy controls (Table 2).
A third independent group of 25 subjects was included to
validate our initial findings using (1) a second microarray platform
(Illumina) and (2) flow cytometry. This validation set was
comprised of 11 patients with S. aureus infection (median age 8
years; 5 MSSA, 6 MRSA) and 13 healthy controls (median age 9
years). PBMCs from 23 subjects were evaluated by flow cytometry
to determine the relative abundance of different immune cell
populations. Simultaneous flow cytometry evaluation and gene
expression analysis was conducted with the same PBMC samples
in 18 (9 with S. aureus infection and 9 healthy controls, matched for
age, sex, race) of these 23 subjects. There were no statistical
differences in extent of disease severity, antimicrobial therapy, or
demographic and laboratory data between the training, test, and
validation sets (Table 3).
Gene expression signature in patients with invasive S.
aureus infections
Statistical group comparison (Mann-Whitney, p,0.01) was
applied to the class comparisons on the quality control (QC) genes
present in the training set revealing 3,168 genes differentially
expressed between S. aureus-infected patients and healthy controls.
These genes were then filtered to include those transcripts with a
1.25-fold or greater change in expression level relative to the
healthy control group, for a total of 3,067 genes. A hierarchical
clustering algorithm was applied to these 3,067 genes in order to
visualize the transcriptional pattern (Figure 1a). For purposes of
validation, the 3,067 gene list comprising the gene expression
profile in PBMC of S. aureus-infected patients was then evaluated
in an independent test set of 22 new patients. The samples were
organized into a condition tree utilizing the 3,067 genes and
correctly classified 31 of 32 samples as either healthy or S. aureus
infection based on the gene expression patterns (Figure 1b).
Genes represented in the expression profile in PBMCs from S.
aureus-infected patients were then ranked according to differences
in both fold-change and significance in gene expression levels
(p,0.05) compared with healthy controls. The top 50 genes that
were significantly over-expressed in patients with S. aureus infection
versus healthy controls are shown in Table 4. Over-expressed
genes included those with microbicidal functions (lactotransferrin,
alpha-defensins 1 and 4, bactericidal/permeability-increasing
protein), involved in coagulation (thrombomodulin), hemoglobin
synthesis (hemoglobin D and G), and pro-inflammatory and
immune-related genes related to pathways of cellular growth,
proliferation, and apoptosis (ADM, ARG1, CLU, EGR1, IL8,
HBEGF, ITGA2B, MMP9) and involved in cell to cell signaling
such as CEACAM6 and CEACAM8.
Module-level analysis reveals over-expression of innate
and under-expression of adaptive immune response
genes
To better characterize the biological significance of the gene
expression profiles seen in the PBMCs of patients with S. aureus
infections, gene expression levels between patients and healthy
controls were mapped using a modular analysis framework that we
recently described [25]. A key to the functional interpretation of
each transcriptional module is detailed in Table S1. Gene
expression levels were compared between patients and healthy
controls on a module-by-module basis. The percentage of genes
with a significant change (Mann-Whitney p,0.05) within each
module are graphically displayed on a module map, with over-
expressed genes represented in red and under-expressed genes in
blue (Figure 2a). Following the approach described previously
with the class comparisons analysis, module analysis was applied
initially to the training set of patients. Patients with S. aureus
infection demonstrated significant over-expression of genes in
modules related to innate immunity including myeloid (M1.5,
M2.6), neutrophil (M2.2), and inflammation (M3.2, M3.3)
modules and under-expression of genes regulating adaptive
immunity such as B cell module M1.3, cytotoxic cell module
S.aureus Alters Monocytes/TCMs
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SUBJECT # AGE (yrs) RACE SEX CONDITION PATHOGEN ANALYSIS PLATFORM
3N 6 H M Control Healthy Training/Test A
5 10 H M Osteomyelitis MSSA Training A
7N 1.6 B F Control Healthy Training/Test A
8N 10 B M Control Healthy Training/Test A
11N 4 B F Control Healthy Training/Test A
23N 7 H F Control Healthy Training/Test A
24 3 B M Bacteremia, Osteomyelitis, Myositis MRSA Test A
24N 3 W M Control Healthy Training/Test A
30 15 B M Bacteremia MRSA Test A
40 13 W M Bacteremia, Osteomyelitis MSSA Training A
43 7 B M Bacteremia, Osteomyelitis, SArthritis,
Pyomyositis, Emboli
MRSA Test A
62 2 W M Osteomyelitis, Pyomyositis MRSA Training A
66 0.25 B F Pneumonia MRSA Test A
67 7 W F Bacteremia, Osteomyelitis MRSA Training A
88 0.92 H M Bacteremia, Osteomyelitis, Pneumonia, Emboli MRSA Test A
90 0.67 B M Bacteremia, SArthritis MSSA Test A
109 0.67 H F Bacteremia, SST Abscess MRSA Training A
150 9 B F Bacteremia, Osteomyelitis, SArthritis, Myositis MRSA Test A
179 12 W M Bacteremia, Endocarditis, Emboli MSSA Training A
205 7 H M Bacteremia, Pneumonia, SST Abscess MRSA Test A
208 10 W F Bacteremia, Osteomyelitis, CNS abscess,
Pneumonia, Emboli
MRSA Test A
216 10 H F Bacteremia, Osteomyelitis MRSA Training A
220 11 H M Bacteremia, Osteomyelitis MSSA Test A
221 6 B F Bacteremia, Osteomyelitis MRSA Training A
224 10 W M Bacteremia, Osteomyelitis MSSA Test A
230 20 B M Bacteremia, Endocarditis, SST Abscess MRSA Test A
241 0.92 B F Bacteremia, Osteomyelitis, Pneumonia MRSA Training A
242 1.2 B M Bacteremia, Osteomyelitis, Pyomyositis MRSA Test A
258 8 W F Bacteremia, Osteomyelitis, Cellulitis MSSA Training A
262 13 H M Bacteremia, SST Abscess MRSA Training A
264 13 B M Bacteremia, Osteomyelitis, SArthritis,
SST Abscess, Myositis, Emboli
MSSA Test A
271 13 B M Osteomyelitis, pyomyositis MSSA Training A
294 12 B F Control Healthy Training/Test A
301 8 W M Control Healthy Training/Test A
303 6 W F Control Healthy Training/Test A
304 6 W M Control Healthy Training/Test A
305 4 H F Bacteremia, Osteomyelitis, SArthritis MSSA Training A
308 12 B F Bacteremia, Pneumonia, Pyomyositis, SST Ab MSSA Training A
328 0.38 B F Bacteremia, Osteomyelitis, Pneumonia, SST
Abscess
MSSA Test A
329 0.58 O F Bacteremia, Lymphadenitis MRSA Training A
330 11 B F Bacteremia, Pneumonia MRSA Test A
354 2 H F Bacteremia, Osteomyelitis MRSA Training A
366 11 B F Osteomyelitis, SST Abscess MRSA Test A
369 14 B M Bacteremia, SArthritis, SST Abscess, Emboli MRSA Test A
372 14 W M Bacteremia, Osteomyelitis, Myositis MRSA Test A
412 1.75 W M Bacteremia, SArthritis MSSA Test A
418 8 H F Osteomyelitis MSSA Training A
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each transcriptional gene profile significantly changed (Mann
Whitney p,0.05) in the PBMCs of patients with S. aureus infection
versus controls are detailed in Figure S1.
Significantly over-expressed genes included those in: M1.5 and
M2.6 (‘‘Myeloid’’), genes related to cells of the myeloid lineage
which are involved in bacterial pathogen recognition such as TLR
2 and CD14, IL10 signaling (CD32, BLVRA) and leukocyte
extravasation signaling (CTNNA1, NCF2, PECAM1, ITGB2),
also in M2.6 genes related to the inflammatory response
(calgranulin B, NFKB inhibitor, TNF superfamily members, and
metalloproteinase inhibitors); in M2.2 (‘‘Neutrophils’’) genes
encoding innate molecules including LTF, DEFA 1 and 4, BPI,
CEACAM 8; in modules M3.2 and M3.3 (‘‘Inflammation I and
II’’) genes involved in inflammatory and endothelial cell processes.
Significant genes found over-expressed in M3.2 (‘‘Inflammation
II’’) included those involved in coagulation (THBD), endovascular
inflammation, TLR signaling (IRAK 3, Ly96), and transcriptional
regulation (zinc finger proteins) while M3.3 included genes
encoding antigens to scavenger receptor proteins (CD36),
coagulation (factor V), and lysosomal functions (LAMP2). A
number of genes were significantly over-expressed in patients
compared to controls in module M2.3 (‘‘erythrocytes’’) related to
hemoglobin (hemoglobin alpha and gamma, erythrocyte mem-
brane protein, erythroid factors) and module M3.5 (‘‘undeter-
mined’’) including hemoglobin alpha and gamma proteins.
Conversely, there was significant under-expression of genes
related to the adaptive immune response including those in M1.3
SUBJECT # AGE (yrs) RACE SEX CONDITION PATHOGEN ANALYSIS PLATFORM
423 8 W M Bacteremia, Osteomyelitis, Pyomyositis MSSA Training A
434 5 W M Osteomyelitis, Pyomyositis MSSA Test A
440 0.5 B M Bacteremia, Osteomyelitis, Pneumonia, Emboli MRSA Training A
450 0.83 B M Bacteremia, Osteomyelitis, SArthritis,
Pyomyositis
MSSA Test A
451 4 H M Bacteremia, Osteomyelitis, SArthritis,
Pyomyositis, Emboli
MRSA Training A
894 8 W F Osteomyelitis, SST Abscess MSSA Validation, FACS I
903 13 W F Control Healthy Validation, FACS I
904 16 W F Control Healthy FACS I
905 16 W F Control Healthy FACS I
907 1.3 H F Bacteremia MRSA FACS I
908 8 B M Bacteremia, Pleural effusion, Pyomyositis, SST
Abscess, Emboli
MSSA FACS I
909 6 H F Bacteremia, Osteomyelitis, SArthritis,
Pneumonia
MRSA Validation, FACS I
910 5 B M Osteomyelitis, SArthritis MSSA Validation, FACS I
922 3 H F Control Healthy FACS I
926 3 H M Control Healthy FACS I
927 2 H M Control Healthy Validation, FACS I
929 11 O F Control Healthy Validation, FACS I
930 8 O M Control Healthy Validation I
931 12 W F Control Healthy FACS I
933 9 W M Control Healthy Validation, FACS I
935 9 W F Control Healthy Validation, FACS I
939 8 W M Control Healthy Validation, FACS I
940 7 W M Control Healthy Validation, FACS I
941 9 W F Control Healthy Validation, FACS I
943 9 W M Osteomyelitis, SArthritis, Pyomyositis MRSA Validation, FACS I
944 6 B F Bacteremia, Osteomyelitis, SArthritis, Pyomyositis MRSA Validation, FACS I
949 11 W M Bacteremia, Osteomyelitis, SArthritis MSSA Validation I
952 15 B M Bacteremia, Osteomyelitis, Pneumonia MRSA Validation, FACS I
954 13 W M Bacteremia, Osteomyelitis, Pyomyositis MSSA Validation, FACS I
960 3 H M Pneumonia MRSA Validation, FACS I
H=Hispanic, W=White, B=Black, O=Other; M=Male, F=Female; SST Ab=Skin/soft tissue abscess, SArthritis=Suppurative arthritis, CNS=central nervous system;
MSSA=methicillin-susceptible Staphylococcus aureus, MRSA=methicillin-resistant Staphylococcus aureus; Platform: A=Affymetrix U133 A&B I= Illumina Sentrix Hu6
BeadChips.
doi:10.1371/journal.pone.0005446.t001
Table 1. Cont.
S.aureus Alters Monocytes/TCMs
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5446(‘‘B cells’’) such as genes encoding cell surface molecules CD19,
CD22, CD72, CD79 and genes involved in immunoglobulin
production, and in M2.8 (‘‘T cells’’) including CD6, CD96, ITK,
and M2.1 (‘‘cytotoxic cells’’) (KLR subfamilies, Granulysin,
Granzyme B) and genes encoding TNF family members. Module
M1.8 (‘‘undetermined’’) included under-expression of factors
involved in DNA replication and transcription (zinc finger protein
genes) and cytokines (IL16); significant under-expressed genes in
M3.8 (‘‘undetermined’’) also included multiple zinc finger proteins
and TNF receptor-associated factors (TRAF5).
The PBMC gene list from S. aureus-infected patients was then
analyzed in the test set of patients and module analysis validated
the initial findings. Both the actual gene probes and the percentage
of over or under-expressed genes per module in patients with S.
aureus infection in the test set matched what had been
demonstrated in the training set of patients, confirming the value
and consistency of the PBMC transcriptional signature in patients
with S. aureus infection (Figure 2a).
Confirming the robustness of the gene expression
signature in S. aureus-infected patients
Twenty-five additional subjects were enrolled to further validate
the PBMC gene expression profile of S. aureus-infected patients by
confirming its reproducibility across microarray platforms. This
validation set was comprised of 11 patients with invasive S. aureus
infections and 14 age and sex-matched healthy controls.
Transcript sequences from RefSeq were used to match corre-
sponding valid gene probe sets on each platform. This allowed
mapping of the 3,067 significant genes comprising the gene
expression profile of PBMC of S. aureus-infected patients based on
the Affymetrix gene probes to their corresponding 1,521 gene
probes on the Illumina platform. This 1,521 gene list was then
applied to the independent validation set of 9 patients and 9
controls using an unsupervised scheme that allowed clustering of
samples based solely on intrinsic gene expression levels
(Figure 2b). Despite technical differences between the two
platforms, all 9 patients with S. aureus infection clustered together
Table 2. Demographic and Laboratory Characteristics of Patients and Controls in Training and Test Sets.
Parameter TRAINING SET TEST SET
Patients Controls p
a Patients Controls p
a
Age (years) 7.5 [2–11] 6 [3.5–9] 0.86 7 [1–12] 6 [3.5–9] 0.93
Race 5B,8H,6W,1O 4B,2H,4W 1 14B,3H,5W 4B,2H,4W 0.25
Gender 9M:11F 5M:5F 0.57 16M:6F 5M:5F 0.45
WBC (thousand/mm
3) 8.9 [7.5–17.4] 7.2 [5.2–8.2] 0.03 11 [7.7–16] 7.2 [5.2–8.2] 0.009
Neutrophils (%) 60 [48–73] 43 [27–50] 0.007 61 [40–66] 43 [27–50] 0.022
Lymphocytes (%) 24 [13–38] 47 [39–55] 0.002 24 [12.7–47] 47 [39–55] 0.038
Monocytes (%) 8 [7–11] 7 [6–10] 0.37 9 [6.3–12.5] 7 [6–10] 0.38
Hematocrit (%) 31.6 [29.8–36] 37.7 [34.9–40] 0.007 30 [27–33.9] 37.7 [34.9–40] 0.002
Platelets (thousand/mm
3) 382 [297–459] 310 [264–329] 0.07 353 [273–445] 310 [264–329] 0.373
CRP (mg/dL) 6.65 [2.1–16.5] 0.4 [0.4–0.7] ,0.001 7.4 [2.3–16.9] 0.4 [0.4–0.7] 0.001
Median values [25–75% range]; B=Black, H=Hispanic, W=White, O=Other; M=Male, F=Female; CRP=C-reactive protein.
ap values calculated within each individual subject set and respective, matched controls (Mann-Whitney).
doi:10.1371/journal.pone.0005446.t002
Table 3. Demographic and Laboratory Characteristics of Patients in Training, Test, and Validation Sets.
S. aureus patients Training Set Test Set Validation Set p-value
a
Age (years) 7.5 [2–11] 7 [1–12] 8 [5–11] 0.82
Race 5B,8H,6W,1O 14B,3H,5W 4B,3H,4W 0.08
Gender 9M:11F 16M:6F 7M:4F 1
WBC (thousand/mm
3) 8.9 [7.5–17.4] 11 [7.7–16] 8.5 [5.7–15.5] 0.52
Neutrophils (%) 60 [48–73] 61 [37–66] 55 [45–71] 0.73
Lymphocytes (%) 24 [13–38.3] 24 [12.7–47.5] 29 [19.5–44.5] 0.70
Monocytes (%) 8 [7–11] 9 [6.3–12.5] 7 [3.5–11.5] 0.58
Hematocrit (%) 31.6 [29.8–36.2] 30 [27.2–33.9] 32 [29–34.1] 0.08
Platelets (thousand/mm
3) 382 [297–459] 353 [273–445] 364 [313–473] 0.61
ESR (mm/hr) 70 [34–98] 46 [36–72] 72 [46–87] 0.28
CRP (mg/dL) 6.7 [2.1–16.5] 7.4 [2.4–16.9] 7.7 [3.7–21.3] 0.69
Median values [25–75% range]; B=Black, H=Hispanic, W=White, O=Other; M=Male, F=Female; CRP=C-reactive protein.
ap values calculated within each individual subject set and respective to matched controls (Kruskal-Wallis).
doi:10.1371/journal.pone.0005446.t003
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patterns alone.
Module level analyses of the 1,521 gene probes on the Illumina
platform demonstrate similarities between the Affymetrix and the
Illumina data. As illustrated in Figure 2b, 16 of 19 modules
yielded concordant results in both the Illumina and Affymetrix
platforms. Only modules M1.4, M3.5, and M3.6 did not show
significant differences in Illumina and may be a result of
representation of less gene probes in those modules. Correlation
analyses of the average normalized values among the differentially
expressed genes for each given module between both platforms
was statistically significant (Spearman R=0.76, p=0.002). Thus,
both unsupervised hierarchical clustering and modular analyses
confirmed the robustness of the gene expression profile in PBMC
of S. aureus-infected patients across both the Affymetrix and
Illumina BeadChip microarray platforms in distinct groups of
subjects.
Decreased number of central memory CD4+ and CD8+ T
cells in patients with S. aureus infections
To understand how the changes in blood transcriptional profiles
in patients with S. aureus infection relate to changes in the numbers
of the different immune cell populations, a detailed flow cytometry
analysis was simultaneously conducted in PBMCs of a subset of
patients with S. aureus (n=11) and appropriate age-matched
healthy controls (n=13).
As illustrated in Figure 3, there were no significant differences
in the total number of B cells and T cells between patients with S.
aureus infection and healthy controls (p.0.05). Given the
significant under-expression of genes related to these cell
populations observed in the modular analysis (M1.3, M2.1,
M2.8), further detailed flow analysis was performed in each
lymphocyte compartment. Characterization of B cell subpopula-
tions revealed no significant differences in the absolute number of
naı ¨ve (CD19+/CD20+, IgD+, CD272), memory (CD19+/
CD20+/IgD+&2/CD27+), and plasma cells (CD19+/CD202/
CD27+&++/CD38++) between patients with S. aureus infections
and healthy controls (Figure 4). Transitional B cells (CD19+/
CD20+/CD24++/CD38++) were increased in patients with S.
aureus infection compared with healthy controls (p=0.04); there
was also a trend (p=0.06) toward increased numbers of pre-
germinal B cells (CD19+/CD20+/CD27+/CD38++) in patients
versus control subjects.
We then analyzed both CD4+ and CD8+ T cell and
subpopulations of naı ¨ve and memory cells based on the expression
of CD45RA, CD62L, and CCR7 as previously described [26]. As
illustrated in Figure 5 there were no differences in the absolute
numbers of naı ¨ve CD4+ T cells and effector memory CD4+ T
Figure 1. Gene expression biosignature in PBMCs from S. aureus patients and healthy controls. (a) Statistical group comparisons
between 10 healthy subjects and 20 patients with acute S.aureus infections yielded 3,067 genes expressed at statistically different levels (Mann-
Whitney p,0.01 and 1.25 fold change) between the two groups. Significant genes were organized by hierarchical clustering to reveal differential
expression, each row representing a single gene and each column an individual subject. Transformed expression levels are indicated by color scale:
red representing relatively high and blue relatively low gene expression compared to the median expression for each gene across all patients
compared to healthy controls. (b) The same 3,067 gene list was used to perform a condition tree on 22 new subjects with S. aureus infections and
correctly grouped 21 of the 22 patients based solely on gene expression.
doi:10.1371/journal.pone.0005446.g001
S.aureus Alters Monocytes/TCMs
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5446Table 4. Top 50 over-expressed genes in invasive S. aureus infections.
Rank Common Name Gene Bank Symbol Description Fold Change Significance
1 LTF NM_002343 Lactotransferrin 46.266 0.000029
2 CEACAM8 M33326 Carcinoembryonic antigen-related cell adhesion molecule 8 31.985 0.000052
3 AW337833 Transcribed locus 32.904 0.000029
4 IL8 NM_000584 Interleukin 8 21.581 0.000075
5 HBG1 NM_000559 Hemoglobin, gamma A 21.543 0.000705
6 DEFA4 NM_001925 Defensin, alpha 4, corticostatin 20.559 0.000075
7 DEFA1 NM_004084 Defensin, alpha 1, myeloid-related sequence 17.011 0.000043
8 HBG2 NM_000184 Hemoglobin, gamma G 15.804 0.001540
9 LCN2 NM_005564 Lipocalin 2 (oncogene 24p3) 13.696 0.000090
10 HBD NM_000519 Hemoglobin, delta 13.327 0.000432
11 ARG1 NM_000045 Arginase, liver 14.386 0.000366
12 BPI NM_001725 Bactericidal/permeability-increasing protein 12.791 0.000129
13 HPR NM_020995 Haptoglobin-related protein 12.218 0.000155
14 S100P NM_005980 S100 calcium binding protein P 11.571 0.000052
15 THBD NM_000361 Thrombomodulin 9.005 0.000309
16 ADM NM_001124 Adrenomedullin 8.670 0.000020
17 CA1 NM_001738 Carbonic anhydrase I 8.627 0.000432
18 ERAF NM_016633 Erythroid associated factor 7.890 0.000155
19 MSCP H69701 Mitochondrial solute carrier protein 7.635 0.000043
20 MYL9 NM_006097 Myosin, light polypeptide 9, regulatory 7.509 0.000510
21 MMP9 NM_004994 Matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa
type IV collagenase)
7.023 0.00580
22 RETN NM_020415 Resistin 6.900 0.000108
23 ANXA3 M63310 Annexin A3 6.465 0.000705
24 CEACAM6 M18728 5.918 0.002400
25 MGAM NM_004668 Maltase-glucoamylase (alpha-glucosidase) 5.823 0.000432
26 PBEF1 AI681868 Pre-B-cell colony enhancing factor 1 5.630 0.001540
27 CYP4F3 NM_000896 Cytochrome P450, family 4, subfamily F, polypeptide 3 5.451 0.000432
28 PBEF AA873350 Pre-B-cell colony enhancing factor 1 5.407 0.000600
29 ITGA2B AF098114 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex,
antigen CD41B)
5.238 0.000827
30 HP NM_005143 Haptoglobin 5.138 0.000035
31 SNCA BG260394 Synuclein, alpha (non A4 component of amyloid precursor) 4.891 0.000016
32 FCGR3A J04162 Fc fragment of IgG, low affinity IIIb, receptor for (CD16) 4.877 0.000029
33 EGR1 AI459194 Early growth response 1 4.422 0.003200
34 LOC199675 BF433657 Hypothetical protein LOC199675 4.420 0.000309
35 SOCS3 AI244908 qj98g11.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:
1867556 39, mRNA sequence.
4.312 0.000013
36 EREG NM_001432 Epiregulin 4.192 0.002070
37 DTR M60278 Heparin-binding EGF-like growth factor 4.087 0.002400
38 TCN1 NM_001062 Transcobalamin I (vitamin B12 binding protein, R binder family) 3.975 0.007280
39 MS4A3 L35848 Membrane-spanning 4-domains, subfamily A, member 3
(hematopoietic cell-specific)
3.966 0.002780
40 GLUL NM_002065 Glutamate-ammonia ligase (glutamine synthase) 3.932 0.000366
41 N63920 FP15737 3.883 0.000062
42 FLJ31978 AI041543 Hypothetical protein FLJ31978 3.879 0.000261
43 CLU M25915 Clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein
2, testosterone-repressed prostate message 2, apolipoprotein J)
3.733 0.000827
44 MAD AW071793 MAX dimerization protein 1 3.715 0.000016
45 H1F0 BC000145 H1 histone family, member 0 3.713 0.000043
46 FCGR1A X14355 Fc fragment of IgG, high affinity Ia, receptor for (CD64) 3.712 0.000029
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the absolute number of central memory CD4+ T cell was
significantly reduced in S. aureus patients compared with controls
(p=0.003). With respect to CD8+ T cells, there were no
differences between S. aureus patients and controls in the number
of naı ¨ve, effector memory, and terminally differentiated CD8+ T
Rank Common Name Gene Bank Symbol Description Fold Change Significance
47 SOCS3 BG035761 Suppressor of cytokine signaling 3 3.708 0.000013
48 MS4A4A NM_024021 Membrane-spanning 4-domains, subfamily A, member 4 3.648 0.001790
49 PBEF NM_005746 Pre-B-cell colony enhancing factor 1 3.611 0.000155
50 ORF1-FL49 AL522667 Putative nuclear protein ORF1-FL49 3.594 0.000155
doi:10.1371/journal.pone.0005446.t004
Table 4. Cont.
Figure 2. Module analysis identifies a specific gene expression profile in the PBMCs of S. aureus-infected patients. (a) Gene expression
levels were compared between patients with S. aureus infections and healthy controls on a module-by-module basis. Colored spots represent the
percentage of significantly over-expressed (red) or under-expressed (blue) transcripts (p,0.05, Mann Whitney) within a module in patients with S.
aureus infections; spot intensity represents the magnitude of the gene expression change, blank modules demonstrate no significant differences
between groups (p.0.05). Information is displayed on a grid, with the coordinates corresponding to one of 28 modules with the key (upper right)
representing the functional interpretation of modules. Nineteen modules are shown to be significantly different between healthy subjects and
patients with S. aureus infection in the training set (a, upper module map). The same gene list applied to the independent test set of patients reveals
the same modular map (a, lower module map). (b) Transcript sequences (RefSeq) were used to map the corresponding 3,067 significant gene probe
sets comprising the gene expression profile of PBMC in patients with S. aureus infection on the Affymetrix platform to their corresponding 1,521 gene
probes on the Illumina platform (b, far left panel) and tested in new S. aureus patients (n=9) and controls (n=9). Module analysis (b, middle panel)
and correlation analyses (Spearman) between the average gene expression levels per module in each platform (b, right panel) were performed.
doi:10.1371/journal.pone.0005446.g002
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CD4+ T cells, central memory CD8+ T cells were also
significantly reduced in S. aureus patients compared with controls
(p=0.005). Thus, PBMCs of patients with invasive S. aureus
infections demonstrate a significant reduction in the numbers of
circulating central memory T cells.
Monocyte expansion in patients with acute S. aureus
infection
As shown in Figure 3, there was a significant increase in the
median total number of monocytes in PBMCs of patients with S.
aureus infection when compared with healthy controls (p=0.002).
Detailed characterization of CD14+ subpopulations showed a
significant increase of absolute number of monocytes expressing
activation markers such as CD86, CD40, HLA-DR, and CD62L
homing lymphocyte molecule in patients with S. aureus infection
compared with controls (Figure 7a). Reanalysis of the CD14+
subpopulations was performed after removing patients with
extreme values (patients 908, 952, or 960) in each subpopulation;
S. aureus patients still demonstrated statistically significant
increased numbers of CD14+ HLADR+ (p=0.023), CD14+
CD40+ (p=0.0076), CD14+ 62L+ (p=0.0062), and CD14+86+
(p=0.0062) when compared to healthy controls.
Based on the CD16 expression, circulating monocytes can be
divided into functionally distinct subpopulations: CD14+CD162
monocytes and CD14+16+ monocytes. Patients with S. aureus
infection showed a significant expansion of both CD14+162
(p=0.0021) and CD14+16+ (p=0.0175) monocytes compared
with healthy controls (Figure 7b). These differences remained
significant even when outliers were removed (CD14+162,
Figure 3. Peripheral blood monocytes are significantly expanded in patients with invasive S. aureus infections. PBMCs obtained from
age-matched healthy donors (n=13) and patients with S. aureus infection (n=11) were analyzed by flow cytometry for the expression of CD19 (left
panel), CD3 (middle), and CD14 (right) markers. Results are expressed as absolute number of cells per mL of blood. Bars represent median values.
Mann-Whitney test was applied for statistical analysis.
doi:10.1371/journal.pone.0005446.g003
Figure 4. Analysis of the B cell compartment. PBMCs obtained from age-matched healthy donors (n=13) and patients with S. aureus infection
(n=11) were stained by multicolor panel staining according to the expression of specific B cell markers. Results are expressed as absolute number of
cells per mL of blood. Bars represent median values. Mann-Whitney test was applied for statistical analysis.
doi:10.1371/journal.pone.0005446.g004
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with invasive S. aureus infections demonstrate a significant increase
in the numbers of circulating monocytes.
Gene expression levels correlate with specific immune
cell populations
To further characterize the relationship between the gene
expression profiles in PBMCs of patients with S. aureus infections
and the changes of the different immune cell populations, analyses
were conducted on a group of patients (n=9) and healthy controls
(n=9) in whom simultaneous gene expression and flow cytometry
analyses were performed. To this end, the per module PBMC
average gene expression obtained from patients with S.aureus
infection relative to the healthy controls, were run on the Illumina
platform and correlated with the absolute number of immune cells
in each subject as measured by flow cytometry (Table 5). The
most significant statistical correlations observed in patients with S.
aureus infections were between the total number of CD14+
monocytes and CD14+ monocyte subpopulations and several
gene expression modules (Figure 8). Absolute number of CD14+
monocytes significantly positively correlated with myeloid cell
(M1.5 and M2.6), neutrophil (M2.2), and inflammation II (M3.3)
modules (Spearman R$0.8, p#0.006). Total CD14+ monocyte
cell numbers inversely correlated with the modules encoding genes
for ribosomal proteins (M2.4) and T cells (M2.8). The number of
CD14+162 cells positively correlated with M2.6 (‘‘Myeloid’’);
CD14+16+ cells correlated with M2.6 (‘‘Myeloid’’). M1.5
(‘‘Myeloid’’), M2.2 (‘‘Neutrophils’’), and M3.3 (‘‘Inflammation
II’’). The absolute number of CD14+CD162 and CD14+CD16+
cells inversely correlated with the ribosomal protein (M2.4) and T
cell (M2.8) modules. Further correlations performed in the
monocyte compartment of CD14+CD62L+, CD14+ HLA-DR+,
CD14+CD40+, and CD14+CD86+ revealed significant positive
correlations between these subpopulations and the myeloid
Figure 5. Analysis of the CD4+ T cell compartment. PBMCs obtained from age-matched healthy controls (n=13) and patients with S. aureus
infections (n=11) were stained with CD3, CD4, CCR7, CD45RA, and CD62L antibodies and analyzed by flow cytometry. CD4 T cell subsets are labeled
as (A) central memory T cells (TCM), (B) naı ¨ve T cells, and (C) effector memory T cells (TEM). (a) Flow cytometry plots of CD4 T cell subsets in a
representative S. aureus patient and healthy control. CD62L expression is shown for each CD4 T cell subset. (b) Graphs show the absolute numbers of
CD4 T cells and CD4 T cell subsets expressed as absolute number of cells per mL of blood. Horizontal lines represent median values. Statistical analysis
was performed using a Mann-Whitney test.
doi:10.1371/journal.pone.0005446.g005
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(M2.6) and T cell (M2.8) modules. Gene expression levels in
modules related to neutrophils (M2.2) and inflammation module II
(M3.3) positively correlated with CD14+CD62L+, CD14+ HLA-
DR+, CD14+CD40+, and CD14+CD86+ cell numbers.
With respect to the T cell compartment, the number of total
CD4+ T cells inversely correlated with the myeloid (M1.5 and
M2.6) and inflammation (M3.3) modules (p=0.0361) (Table 5).
Numbers of naı ¨ve CD4+ T cells positively correlated with the
modules related to ribosomal proteins (M2.4) and T cells (M3.8),
while inversely correlating with the M2.6 (Myeloid) and
inflammation (M3.2 and M3.3) modules. The number of CD4+
T central memory cells (TCM) correlated inversely with myeloid
(M1.5 and M2.6), neutrophil (M2.2), and inflammation (M3.3)
modules, but positively with the ribosomal protein (M2.4), T cell
(M2.8), and interferon (M3.1) modules. CD8+ T central memory
cell numbers correlated inversely with myeloid modules (M1.5 and
M2.6) and inflammation (M3.3) modules; conversely, CD8+ T
effector memory cells correlated positively with cytotoxic cell
module (M2.1) and undetermined (M1.8 and M3.7) modules.
There were no significant correlations between modular gene
expression levels and CD4+ T effector memory, CD8+ naı ¨ve, and
CD8+ terminally differentiated T cells. There were no significant
correlations between the total number of CD19+ B cells, nor B cell
subpopulations such as naı ¨ve B cells, memory B cells, transitional
B cells, pre-germinal center B cells, and plasma cells B cell and
modular gene expression patterns (Table S2).
Discussion
The versatility of S. aureus has allowed emergence of highly
resistant and virulent bacterial strains in the community [27]. Its
pathogenicity is in part due to its repertoire of virulence factors
and proclivity for tissue and endovascular invasion, destruction,
and dissemination while simultaneously evading multiple compo-
nents of the innate immune system and secreting immunomod-
ulatory proteins that compromise both humoral and cell-mediated
immunity [7,27,28]. Very little is known about the relationship
between the human host and S. aureus during invasive infections,
leading us to carry out the present study. We chose to apply a
systems biology approach utilizing both gene expression micro-
array profiling and corresponding flow cytometry analyses to allow
for a comprehensive assessment of the immunopathogenesis of the
disease and interaction with the host.
Figure 6. Analysis of the CD8+ T cell compartment. PBMCs obtained from patients with S. aureus infections (n=11) and age-matched healthy
controls (n=13) were stained with CD3, CD8, CCR7, CD45RA, and CD62L antibodies and analyzed by flow cytometry. CD 8 T cells and CD 8 T cell
subsets are labeled as: (A) central memory T cells (TCM); (B) naı ¨ve T cells, (C) effector memory T cells (TEM), and (D) terminally differentiated effector T
cells (TEM). (a) Flow cytometry plots show CD8 T cell subsets in a representative S. aureus patient and healthy control. CD62L expression is shown for
each CD8 T cell subset. (b) Graphs show the absolute numbers of CD8 T cells and CD8 T cell subsets. Results are expressed as absolute number of
cells per mL of blood. Horizontal lines represent median values. Statistical analysis was performed using a Mann-Whitney test.
doi:10.1371/journal.pone.0005446.g006
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expression profile of patients with invasive S. aureus infections was
defined and its robustness validated among distinct patient
populations and across microarray platforms. Modular analysis
demonstrated significant activation of host genes related to the
innate immune response with increased expression of genes related
to inflammatory processes and cells of the myeloid lineage and
significant under-expression of genes related to the adaptive
Figure 7. Analysis of monocyte compartment. PBMCs obtained from patients with S. aureus infections (n=11) and age-matched healthy
controls (n=13) were stained with Monocytes expressing HLA DR, CD40, CD62L, CD16, and CD86 antibodies and analyzed by flow cytometry. (a)
Graphs show the absolute monocyte cell numbers. Results are expressed as absolute number of cells per mL of blood. Horizontal lines represent
median values. Statistical analysis was performed using a Mann-Whitney test. (b) There was a significant expansion of both the CD14+ CD162 and
the CD14+ CD16+ monocyte populations as shown in a flow cytometry plot of a representative S. aureus patient (907) and healthy control (933).
doi:10.1371/journal.pone.0005446.g007
Table 5. Correlation of gene expression levels and absolute number of immune cells in patients with S. aureus infections.
FACS Cell Marker Module Assigned Immune Function Correlation (Spearman) p-value
CD19 none
CD3 none
CD4 M1.5 Myeloid 20.683 0.0361
M2.6 Myeloid 20.650 0.05
M3.3 Inflammation II 20.683 0.0361
CD8 M3.1 Interferon 0.65
NK none
CD14 M1.3 B cells 20.633 0.0583
M1.5 Myeloid 0.85 ,0.001
M2.2 Neutrophils 0.8 0.006
M2.4 Ribosomal 20.95 ,0.001
M2.6 Myeloid 0.933 ,0.001
M2.8 T cells 20.95 ,0.001
M3.3 Inflammation II 0.9 ,0.001
FACS=fluorescence-activated cell sorting; NK=Natural Killer cell.
doi:10.1371/journal.pone.0005446.t005
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immune response genes was not unexpected [28,29], the striking
and consistent decreased expression of B and T cell-related genes
was less anticipated.
There is limited and conflicting information regarding the
numbers of lymphocyte populations in patients with acute S. aureus
infections [30–33]. In one study, patients with S. aureus and S.
pneumoniae sepsis showed significantly decreased numbers of CD4+
and CD8+ T cells, and NK cells [34] while in another, patients
with MRSA superantigen-associated glomerulonephritis showed
increased numbers of DR+ CD4+ and CD8+ T cells and NK cells
[35]. Flow cytometry analyses were performed in our study
subjects to better understand whether the changes observed in the
gene expression patterns simply reflected alterations in immune
cell numbers. Despite significant under-expression of T and B cell-
related genes observed in our patients with S. aureus infections,
there were no differences in the absolute numbers of total B and T
cells between infected patients and healthy controls. No consistent
significant differences were seen between patients and controls
across B cell subpopulations evaluated, however there were
possible trends in transitional and pre-germinal B cells that will
require analysis in a larger sample size.
Detailed analysis of the T cell sub-populations revealed
decreased numbers of both central memory CD4+ T cells and
CD8+ T cells, but no differences in the other T cell subsets in
patients with S. aureus infection. Central memory T cells have
been shown to have a high proliferative potential and to
demonstrate in vivo persistence [36,37]. Our results demonstrate a
decreased number of central memory T cells, suggesting a
possible reorganization of the circulating T cell compartment
that may also explain the reduced expression of T cell-related
genes. With increased expression of CCR7 and CD62L, central
memory T cells are programmed to preferentially migrate to
lymphoid tissues to interact with other T and B cells in
establishing a repertoire of effector functions against the invading
pathogen [26]. One possible explanation then, for the significant
reduction in the numbers of circulating central memory T cells
seen in our subjects with S. aureus infection may be central
memory T cell homing to these secondary lymph organs. S.
aureus expresses factors that promote its immune evasion and
could also elicit this cellular imbalance. In vitro observations have
demonstrated a shift from central memory to effector memory T
cells in the presence of S. aureus enterotoxin [26]. Secretion of
other superantigens by S. aureus, such as Map/Eap (MHC Class
II analogous protein/extracellular adherence protein), bind to T-
cell receptors and directly thwart T cell responses by reducing T
cell proliferation, altering effector functions, and stimulating
apoptosis [7].
Alternatively, the under-expression of T cell genes may be
due to an increase in other cell populations. Indeed, the
monocyte compartment, total number and subpopulations, was
significantly expanded in patients with S. aureus infection and
correlated with gene expression levels, providing the cellular
component to the increased expression of innate immune
genes. Based on CD16 expression, circulating monocytes can
be divided into functionally distinct subpopulations
CD14+CD162 and CD14+16+ monocytes, which may have
distinct roles in the innate immune response [38]. In the S.
aureus patients, there was a significant expansion of both of
these monocyte subsets. Furthermore, the high levels of
expression of genes generally associated with neutrophil
functions, such as defensins, lactotransferrins, CAMP, and
elastase, as seen in module M2.2, may originate from the
CD14+16+ (CD62L2) monocytes subset, as has been recently
described [38]. Although significant numbers of neutrophils are
not generally present in PBMCs, low-density neutrophils have
been demonstrated and accounted for over-expression of
neutrophil genes in patients with SLE [39]. Despite using
similar technical approaches, we were not able to detect neither
these low-density immature neutrophils nor high-density
neutrophils that could result from contamination in our
samples. Studies with purified cell subsets will be necessary to
understand the distinct contribution from each cell subtype.
These results demonstrate the value of gene expression profiling
in combination with flow cytometry as a new strategy to study
disease pathogenesis within the clinical context. This study
provides information on the profound dysregulation of both the
innate and adaptive immune responses induced by invasive S.
aureus infections and opens new avenues for improving our
understanding of this infection that may lead to improved
biomarker discovery and therapeutic interventions.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Boards of the University of Texas South-
western Medical Center and Children’s Medical Center of Dallas
(IRB #0802-447) and Baylor Institute of Immunology Research
(BIIR, IRB # 002-141). Informed consent was obtained from legal
guardians and informed assent was obtained from patients 10
years of age and older prior to any study-related procedure.
Patient information
Blood samples were collected from 77 children: 53 patients with
S. aureus infection and 24 healthy controls. Children with suspected
or proven polymicrobial infections, underlying chronic disease,
immunodeficiency, or those who received steroids or other
immunomodulatory therapies were excluded. Control samples
were obtained from healthy children undergoing elective surgical
procedures and at healthy outpatient clinic visits. Nasopharyngeal
viral cultures were obtained in both patients and controls to
exclude viral co-infections. Children hospitalized with acute S.
aureus infections were offered participation in the study after
microbiologic confirmation of the diagnosis by standard bacterial
culture of blood or tissue specimens. Patients were analyzed in 3
groups: training (20 S. aureus, 10 healthy), test (22 S. aureus,1 0
healthy), and validation sets (11 S. aureus, 14 healthy).
Sample collection
Blood samples (3–8 mL) were collected in acid-citrate-dextrose
tubes (ACD tubes, BD Vacutainer, Franklin Lakes, NJ) and
delivered to the laboratory at room temperature for processing.
Figure 8. Significant correlations between absolute and subpopulations of monocytes and modular gene expression in patients
with S. aureus infection. Correlation analyses were performed between the significant modules comprising the gene expression profile of PBMCs
from S. aureus-infected patients and monocyte populations. Graphs represent the correlation (Spearman) between the average normalized average
gene expression [log] significantly changed (Mann Whitney p,0.05) in the PBMCs of patients with S. aureus infection relative to the median gene
expression of PBMCs in healthy controls in each significant module (y axis) and the corresponding absolute monocyte number and CD14+
subpopulations per mL of blood in S. aureus-infected patients (x axis).
doi:10.1371/journal.pone.0005446.g008
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density gradient centrifugation using Ficoll-hypaque technique and
lysed in RLT reagent (Qiagen, Valencia, CA) with b-mercaptoeth-
anol (BME) and stored at -80uC until processing. Samples were run
in batches by the same laboratory team to ensure standardization of
quality and handling of samples. Total RNA was isolated using the
RNeasy Mini Kit (Qiagen, Valencia, CA) per the manufacturer’s
instructions and RNA integrity was assessed using an Agilent 2100
Bioanalyzer (Agilent, Palo Alto, CA).
Microarray procedures
Affymetrix. From 2–5 micrograms of total RNA, double-
stranded cDNA was generated as a template for single-round in
vitro transcription with biotin-labeled nucleotides using the
Affymetrix cDNA Synthesis and In Vitro Transcription kits
(Affymetrix Inc., Santa Clara, CA). Biotinylated cRNA targets
were then purified (Sample Cleanup Module, Affymetrix) and
hybridized to the Affymetrix HG-U133A and B GeneChip arrays
(Affymetrix Inc., Santa Clara, CA) according to the
manufacturer’s standard protocols.
Affymetrix Gene Chips. Arrays were scanned using a laser
confocal scanner (Agilent). Global gene expression analysis was
carried out using the Affymetrix HG-U133A and U133B
GeneChips. The HG-U133 set contains 44,760 probe sets
representing .39,000 transcripts derived from ,33,000 human
genes. Raw signal intensity values were normalized to the mean
intensity of all measurements per gene chip and scaled to a target
intensity value of 500 using the MAS 5.0 global scaling method to
adjust for possible chip-to-chip variations in hybridization
intensities (GeneChip Operating System version 1.0). Data was
imported into GeneSpring software (version 7.3.1, Agilent) to
perform the gene expression analyses, statistical testing,
hierarchical clustering, and classification of samples.
Illumina: Double-stranded cDNA was obtained from 200 ng of
total RNA and after in vitro transcription underwent amplification
and labeling steps according to the manufacturer’s instructions.
1.5 mg of amplified biotin-labeled cRNA was hybridized to the
Illumina Sentrix Hu6 BeadChips according to the sample labeling
procedure recommended by Illumina. (Ambion, Inc, Austin, TX).
Illumina BeadChips: The Sentrix Hu6 BeadChips consist of 50mer
oligonucleotide probes attached to 3-mm beads within microwells
on the surface of the glass slide representing 48,687 probes. Slides
were scanned on Illumina BeadStation 500 and Beadstudio
software was used to assess fluorescent hybridization signals.
Microarray Data Analysis
Using the Genespring
TM software program (Agilent), the
expression value for each gene per individual subject’s sample
was normalized to the median expression value of the same gene
in samples from healthy controls. Class comparison analyses were
performed on probe sets present in at least 75% of samples in each
group (quality control (QC) probes). Non-parametric statistical
testing (Wilcoxon-Mann-Whitney U-test; p,0.01 for class com-
parisons; p,0.05 for modular analyses with no multiple test
corrections) was used to rank genes based on their ability to
discriminate among pre-specified groups of patients. Final lists of
significantly changed genes used in class comparisons were filtered
to include only those transcripts that showed a 1.25-fold or greater
fold change in expression level relative to the control group.
Hierarchical clustering was applied to order genes according to
expression levels. The list of most highly ranked genes from the S.
aureus biosignature was created by ranking genes with the highest
fold change difference and the most significantly different genes
(by p value) between healthy controls and patients with infection.
For the cross microarray platform validation part of the analysis
we performed a two-step procedure. First, we examined the genes
that defined the S. aureus biosignature obtained on the test and
training set of subjects analyzed on the Affymetrix platform in a
new set of 18 subjects (validation set) and run on the lllumina
microarray platform. Transcript sequences from RefSeq were used
to perfectly match corresponding valid gene probe sets on each
platform; Affymetrix probe set data encoded by Mage-ML files in
XML format were matched by GenBank accession numbers and
reference sequence transcripts to the Illumina manifest probe
mapping file (http://www.switchtoi.com/probemapping.ilmn) al-
lowing for mapping of the significant Affymetrix gene probes to
their corresponding gene probes on the Illumina platform. In the
second step of the analysis, the Illumina gene list was applied to an
independent validation set of subjects using an unsupervised
scheme that allowed clustering of samples based solely on intrinsic
gene expression levels.
Transcriptional Module Analysis
A detailed account of this module-based data mining analysis
strategy has been reported elsewhere [25]. Briefly, this is a systems-
scale strategy for microarray analysis that has identified transcrip-
tional modules formed by genes coordinately expressed across
multiple disease data sets thus allowing functional interpretation of
the microarray data into biologically useful information. Analysis
of linear correlations between gene expression levels per module in
the different microarray platforms (Affymetrix vs. Illumina) and
between the average gene expression levels per module (from the
validation set run on Illumina) and the individual immune cell
numbers per patient (calculated by Flow cytometry) were
performed using a non-parametric statistical correlation analysis
test (Spearman).
Flow cytometry
PBMCs were isolated by density gradient centrifugation using
Ficoll-hypaque technique from blood samples (3–8 mL) collected in
ACD tubes. One million PBMCs were washed and incubated with
conjugated antibodies for 15 minutes at room temperature, in dark
conditions according to multi-color staining panels described below.
Cells were washed with phosphate buffer and then fixed with 2%
paraformaldehyde. Samples were run on a BD LSRII flow cytometer
(BD BioScience, San Jose, CA); 50,000 events were acquired with the
BD FACSDiva
TM software according to the lymphocyte gate and
analyzed using FlowJo
TM software (Tree Star, Inc).
Multicolor staining panels included: B cell panel: CD19 (ECD,
Beckman-Coulter), CD20 (Pe-Cy5, BD Pharmingen), CD24 (PE,
BD Pharmingen), CD27 (APC, BD Pharmingen), CD38 (Pe-Cy7,
BD Biosciences) and IgD (FITC, SouthernBiotech). T cell panel:
CD3 (Alexa700, BD Pharmingen), CD4 (Pacific Blue, Invitrogen),
CD8 (APC-Cy7, BD Pharmingen), CD45RA (ECD, Beckman-
Coulter), CD62L (Pe-Cy5, BD Pharmingen), CCR7 (Pe-Cy7, BD
Pharmingen). Monocyte panel: CD14 (Pacific Blue, BD Pharmin-
gen), CD16 (APC, Invitrogen), CD40 (PE, BD Pharmingen),
CD86 (FITC, BD Pharmingen), HLA-DR (APC-Cy7, BD
Pharmingen) and CD62L (ECD, Beckman-Coulter). Isotype
controls: IgG1 (FITC, BD Biosciences), IgG1 (PE, BD Bioscienc-
es), IgG1 (ECD, Beckman-Coulter), IgG1 (Pe-Cy5, BD Bioscienc-
es), IgG1 (Pe-Cy7, BD Biosciences), IgG1 (APC, BD Biosciences),
IgG1 (Alexa 700, BD Biosciences), IgG1 (APC-Cy7, BD
Biosciences), IgG1 (Pacific Blue, Invitrogen).
Cell populations were analyzed based on the following markers:
B cells: CD19; Naı ¨ve B cells: CD19+/CD20+, IgD+, CD272;
Memory B cells: CD19+/CD20+/IgD+&2/CD27+; Plasma cells:
CD19+/CD202/CD27+&++/CD38++; Transitional B cells:
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CD19+/CD20+/CD27+/CD38++; T cells: Naı ¨ve T cells: CD3+/
CD4+ or CD8+/CD45RA+/CCR7+; Central memory T cells:
CD3+/CD4+ or CD8+/CD45RA2/CCR7+; Effector memory T
cells: CD3+/CD4+ or CD8+/CD45RA2/CCR72; CD8+ ter-
minally differentiated T cells: CD3+/CD8+/CD45RA+/
CCR72.
Online Supporting Information
Table S1 provides the functional interpretation of the
transcriptional modules including module, number of probe tests
evaluated, key words included in data mining, and immune
interpretation. Table S2 details the results of the non-parametric
correlation analyses performed between B and T cell populations
and module analyses. Figure S1 provides graphic representation
and detailed information regarding significantly differently ex-
pressed genes in patients with S. aureus infection versus healthy
control per module.
Accession Numbers
The microarray data used in this study is deposited in NCBI
Gene Expression Omnibus (GEO).
Supporting Information
Table S1 Functional interpretation of transcriptional modules.
Found at: doi:10.1371/journal.pone.0005446.s001 (0.06 MB
DOC)
Table S2 Correlations of B and T cell subsets with transcrip-
tional modules.
Found at: doi:10.1371/journal.pone.0005446.s002 (0.05 MB
DOC)
Figure S1 Module analysis of the gene expression profile in
patients with S. aureus infections. Graphs represent the average
gene expression level (y axis) significantly changed (Mann Whitney
p,0.05) in patients with S. aureus infections (x axis, red horizontal
bar) versus healthy controls (x axis, green horizontal bar) in each of
the 19 significant modules (M) comprising the gene expression
profile seen in PBMCs of S. aureus-infected patients. A detailed list
citing the gene probe, pvalue, and description of the significant
transcript is noted.
Found at: doi:10.1371/journal.pone.0005446.s003 (0.57 MB
DOC)
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